

Balance 3770

Date	10/07/2021	Srl No.	19	Company	OPD
Name	MR. SUDHEER SARAF	Age	59 Yrs.	Sex	M
Ref. By	MEDIWHEEL				

Test Name	Value	Unit	Reference Value
<u>HAEMATOLOGY</u>			
HAEMOGLOBIN (Hb)	12.5	gm/dl	13.5 - 18.00
TLC (Total Leucocyte Count)	5800	/cumm	4000 - 11000
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHIL	63	%	45 - 75
LYMPHOCYTE	32	%	20 - 45
EOSINOPHIL	03	%	1 - 6
MONOCYTE	02	%	1 - 10
R B C (Red Blood Cell Count)	4.47	Millions/cmm	4.2 - 5.4
PLATELET COUNT	192	x10 ³ /uL	150 - 450
Hct (Hematocrit/PCV)	38.9	%	40 - 54
M C V (Mean Corp Volume)	87.025	fL	80.0 - 99.9
M C H (Mean Corp Hb)	27.964	pg	27.0 - 31.0
M C H C (Mean Corp Hb Conc)	32.134	g/DL	33.0 - 37.0
E.S.R. (Wintrobe)	19	mm/1st hr.	0.00 - 20
BLOOD GROUP ABO	'O'		
RH TYPING	POSITIVE		

The upper agglutination tes for grouping has some limitations.
For further confirmation Resverse typing Card (Dia clon ABO/D) Method is suggested.

GLYCATED HAEMOGLOBIN (HbA1c)

<u>INVESTIGATION</u>	<u>OBSERVED VALUE</u>	<u>UNIT</u>
GLYCOSYLATED HAMOGLOBIN (HbA1c)	: . 6.6	%

Contd...2

Balance 3770

Date	10/07/2021	Srl No.	19	Company	OPD
Name	MR. SUDHEER SARAF	Age	59 Yrs.	Sex	M
Ref. By	MEDIWHEEL				

Test Name	Value	Unit	Reference Value
REFERANGE RANGE (HBA1C) :			
GOOD CONTROL	: 4.5 - 6.4	%	
FAIR CONTROL	: 6.5 - 7.4	%	
POOR CONTROL	: ABOVE 7.5	%	
REFERANGE RANGE (AVERAGE BLOOD SUGAR) :			
EXCELLENT CONTROL	: 90-120	MG/DL	
GOOD CONTROL	: 121-150	MG/DL	
AVERAGE CONTROL	: 151-180	MG /DL	
ACTION SUGGESTED	: 181-210	MG/DL	
PANIC VALUE	: > 211	MG/DL	

NOTE : AVERAGGE BLOOD SUGAR VALUES IS CALCULATED FROM HBA1C VALUE AND IT INDICATED AVERAGE BLOOD

BIOCHEMISTRY

BLOOD GLUCOSE PP	219.0	mg/dl	upto to 140
BLOOD UREA	35.2	mg/dl	13 - 45
SERUM CREATININE	1.17	mg/dl	0.7 - 1.4
SERUM BILIRUBIN	0.94	mg/dl	0.0 - 2.0
CONJUGATED (D. Bilirubin)	0.66	mg/dl	0.00 - 0.2
UNCONJUGATED (I. D. Bilirubin)	0.28	mg/dl	0.00 - 0.7
SGOT/AST	30.5	U/L	0 - 35
SGPT/ALT	28.2	U/L	0 - 40
ALKALINE PHOSPHATASE	102.5	IU/L	25 - 140
Gamma GT	30.8	U/L	10 - 50
TOTAL PROTEIN	7.09	gm/dl	6.4 - 8.0
ALBUMIN	4.05	gm/ dl	3.5 - 5.5
GLOBULIN	3.04	gm/dl	2.3 - 3.6
A/G RATIO	1.332		1.0 - 2.3

Contd...

Balance 3770

Date	10/07/2021	Srl No.	19	Company	OPD
Name	MR. SUDHEER SARAF	Age	59 Yrs.	Sex	M
Ref. By	MEDIWHEEL				

LIPID PROFILE

SERUM CHOLESTEROL	172.0	mg/dl	0 - 200
			Normal Risk <200 mg/dl
			Borderline Risk 200-239 mg/dl
			High Risk > 239 mg/dl
SERUM TRIGLYCERIDES	220.8	mg/dl	60 - 165
			Normal Risk <150 mg/dl
			Border Line: 150-199
			High Risk: 200-499
			Very High Risk: >499
HDL CHOLESTEROL	40.8	mg/dl	35 - 79.5
LDL CHOLESTEROL	131.2	mg/dl	100 - 160
VLDL	44.16	mg/dl	0.00 - 35
TOTAL / HDL CHOLESTEROL RATIO	4.216		0.00 - 4.9
LDL / HDL CHOLESTEROL RATIO	3.216		0.00 - 3.5

URINE EXAMINATION REPORT

PHYSICAL EXAMINATION

COLOUR	STRAW CLEAR
VOLUME	40 ml.
SPECIFIC GRAVITY	1.020
DEPOSIT	NIL

CHEMICAL EXAMINATION

REACTION	5.0
ALBUMIN	TRACES
SUGAR	NIL

Balance 3770

Date	10/07/2021	Srl No.	19	Company	OPD
Name	MR. SUDHEER SARAF	Age	59 Yrs.	Sex	M
Ref. By	MEDIWHEEL				

Test Name	Value	Unit	Reference Value
BILE SALTS (BS)	ABSENT		
BILE PIGMENT (BP)	ABSENT		
PHOSPHATE	ABSENT		
MICROSCOPIC EXAMINATION			
PUS CELLS	2-3	/HPF	
EPITHELIAL CELLS	1-2	/HPF	
RBC'S	NIL	/HPF	
CASTS	NIL		
CRYSTALS	NIL		

ENDOCRINOLOGY

THYROID FUNCTION TEST

TOTAL T3	102.9	ng/dL	60.00 - 181.00
TOTAL T4	8.9	ug/dL	4.5 - 10.9
THYROID STIMULATING HORMONE (TSH) CLIA	3.99	uIU/mL	0.35 - 5.50

CANCER MARKER

CANCER MARKERS (VIDAS)

PROSTATIC SPECIFIC ANTIGEN

<u>INVESTIGATION</u>	<u>REPORT BY CLIA</u>	<u>OBSERVED VALUE</u>	<u>UNIT</u>
PROSTATIC SPECIFIC ANTIGEN (P.S.A.)	:	1.69	ng/ mL

NORMAL RANGE :

Reference range

Contd..

Balance 3770

Date	10/07/2021	Srl No.	19	Company	OPD
Name	MR. SUDHEER SARAF	Age	59 Yrs.	Sex	M
Ref. By	MEDIWHEEL				

Test Name	Value	Unit	Reference Value
AGE	- < 40 years	0.21 to 1.72	ng/ml
	40-49	0.27 to 2.19	ng/ml
	50-59	0.27 to 3.42	ng/ml
	60-69	0.22 to 6.16	ng/ml
	> 69	0.21 to 6.77	ng/ml

Comment : the fact of PSA is unique to prostate tissue makes it a suitable marker for monitoring men with cancer of the prostate. PSA is also useful for determining possible recurrence after therapy. Measurement of serum PSA levels is not recommended as a screening procedure for the diagnosis of cancer because elevated PSA levels also are observed in patients with benign prostatic hypertrophy.

** End of Report **

Reported by : RAM

Checked by : _____